Revolution Medicines AI Stock Analysis
Revolution Medicines (42Z) AI Stock Analysis
Revolution Medicines
(XETRA:42Z)
No summary available
Revolution Medicines (42Z) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 34.57B
- Dividend Yield
- ―
- Average Volume (3M)
- 283
- Price to Earnings (P/E)
- -17.5
- Beta (1Y)
- 0.80
- Revenue Growth
- ―
- EPS Growth
- -67.73%
- Country
- Germany
- Employees
- 883
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Revolution Medicines Business Overview & Revenue Model
Company Description
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug c...
Revolution Medicines Earnings Call Summary
The call was strongly positive, driven by FDA approval, a rapid initial U.S. launch generating $198 million in revenue from more than 5 thousand commercial patients, broad early physician and payer access, positive regulatory progress in Europe, and continued advancement across pancreatic, lung, colorectal, and earlier-stage RAS(ON) programs. The principal challenges were that launch revenue includes finite early cohorts, normalized demand remains uncertain, formal payer policies are still developing, European approval is pending, and expenses and net loss increased substantially. Overall, the number and significance of the achievements materially outweighed the stated challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company reiterated guidance for full year 2026 GAAP operating expenses of $2.1 billion to $2.2 billion, including expected noncash stock based compensation expense of $270 million to $290 million, and said full year 2027 GAAP operating expenses are expected to increase from the current GAAP operating expense run rate, with no specific range provided; it expects to manage channel inventory at approximately 2 weeks over the long run, while the quarter ended with less than 2 weeks of inventory, and expects the gross to net discount to increase within the anticipated 20% to 30% range; global enrollment in RASolute 303 is expected to complete in the first half of 2027, the initial phase 3 readout for RASolve 301 is planned in 2027, initial clinical monotherapy data for RMC-7 are expected in 2027, RM-005 remains on track for initiation of its first in human clinical study in the fourth quarter, and the company expects to provide a colorectal cancer clinical data update in the first half of 2027.
Revolution Medicines Risk Analysis
Revolution Medicines disclosed 86 risk factors in its most recent earnings report. Revolution Medicines reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksRevolution Medicines Peers Comparison
Overall Rating
EXEL81Outperform
INCY73Outperform
GMAB63Neutral
BNTX49Neutral
RLAY44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $16.71B | 19.79 | 45.54% | ― | 9.12% | 40.53% | |
| 73Outperform | $24.27B | 56.09 | 7.11% | ― | 24.88% | -65.67% | |
| 63Neutral | $30.80B | 43.21 | 12.26% | ― | 19.61% | -50.40% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $21.04B | -12.92 | -8.09% | ― | -20.72% | -160.57% | |
| 44Neutral | $3.65B | -10.93 | -40.25% | ― | 23.86% | 13.76% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:42Z | Revolution Medicines, Inc. | 146.25 | 83.75 | 134.00% | |
| EXEL | Exelixis | 68.29 | 25.78 | 60.64% | |
| INCY | Incyte | 117.80 | 15.74 | 15.42% | |
| GMAB | Genmab (Otc) | 50.97 | 20.52 | 67.39% | |
| BNTX | Biontech Se Sponsored Adr | 83.26 | -12.33 | -12.90% | |
| RLAY | Relay Therapeutics Inc | 16.51 | 9.74 | 143.87% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
